Clinical trials: Post-polio Syndrome

Post-polio Syndrome

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

• Terminated
• Age: 18 to 75 years
• Phase 2/3
• Results posted

This was a multicenter, prospective, randomized, placebo-controlled, double-blind, parallel group clinical trial with adaptive dose selection in participants with post-polio syndrome (PPS).

Trial name

FORCE (NCT02176863)

Testing

Flebogamma® 5% DIF

Where

21 sites in United States, Canada and 7 more

Volunteers

191 people

Sponsor

Instituto Grifols, S.A.